celares GmbH is specialist for PEGylation, a special form of drug delivery for biopharmaceuticals, especially for peptide and protein drugs, respectively. The company holds patent applications for a new class of branched, monodispersed PEG reagents of unique quality. Using these PEG-reagents the half-life of biopharmaceuticals is significantly prolonged by decelerating renal excretion, reducing immunogenicity, increasing stability towards proteases and improving solubility. In addition to this new class of PEG-reagents celares GmbH provides contract developmental services and synthesis of customized reagents.